STOCK TITAN

Eyenovia Announces Publication of Study Demonstrating Favorable Impact on the Ocular Surface of Medication Delivered with the Optejet®

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags

Eyenovia (NASDAQ: EYEN) announced two significant developments for its Optejet® dispenser. A study published in the Journal of Ocular Pharmacology and Therapeutics demonstrated that Optejet can deliver latanoprost with significantly less exposure to harmful preservatives compared to traditional eye drops, avoiding cytotoxicity associated with larger volumes. Additionally, a Phase 4 study of Mydcombi, presented at the American Academy of Optometry, showed that a half-dose achieved clinically relevant pupil dilation with favorable safety outcomes. The study reported mean pupil diameter changes from 2.74mm at baseline to 6.42mm after 30 minutes, with 67% of eyes dilated to ≥6mm.

Eyenovia (NASDAQ: EYEN) ha annunciato due sviluppi significativi per il suo distributore Optejet®. Uno studio pubblicato nel Journal of Ocular Pharmacology and Therapeutics ha dimostrato che Optejet può somministrare latanoprost con un'esposizione significativamente inferiore a conservanti dannosi rispetto ai classici colliri, evitando la citotossicità associata a volumi maggiori. Inoltre, uno studio di Fase 4 su Mydcombi, presentato all'American Academy of Optometry, ha mostrato che una mezza dose ha raggiunto una dilatazione pupillare clinicamente rilevante con risultati di sicurezza favorevoli. Lo studio ha riportato cambiamenti medi nel diametro pupillare da 2,74 mm al basale a 6,42 mm dopo 30 minuti, con il 67% degli occhi dilatati a ≥6 mm.

Eyenovia (NASDAQ: EYEN) anunció dos desarrollos significativos para su dispensador Optejet®. Un estudio publicado en el Journal of Ocular Pharmacology and Therapeutics demostró que Optejet puede administrar latanoprost con una exposición significativamente menor a conservantes dañinos en comparación con las gotas para los ojos tradicionales, evitando la citotoxicidad asociada con volúmenes mayores. Además, un estudio de Fase 4 de Mydcombi, presentado en la American Academy of Optometry, mostró que una media dosis logró una dilatación pupilar clínicamente relevante con resultados de seguridad favorables. El estudio informó cambios en el diámetro pupilar medio de 2,74 mm al inicio a 6,42 mm después de 30 minutos, con el 67% de los ojos dilatados a ≥6 mm.

Eyenovia (NASDAQ: EYEN)Optejet® 디스펜서에 대한 두 가지 중요한 개발 소식을 발표했습니다. Journal of Ocular Pharmacology and Therapeutics에 발표된 연구에 따르면, Optejet는 기존의 안약에 비해 해로운 방부제 노출을 상당히 줄이면서 latanoprost를 전달할 수 있으며, 큰 용량과 관련이 있는 세포독성을 피할 수 있습니다. 또한, American Academy of Optometry에서 발표된 Mydcombi의 4상 연구에서는 반 용량으로 임상적으로 유의미한 동공 확장을 달성하면서 안전성 결과가 우수함을 보여주었습니다. 연구 결과, 기준선에서 30분 후에는 평균 동공 직경이 2.74mm에서 6.42mm로 변화했으며, 67%의 눈이 ≥6mm로 확장되었습니다.

Eyenovia (NASDAQ: EYEN) a annoncé deux développements importants pour son distributeur Optejet®. Une étude publiée dans le Journal of Ocular Pharmacology and Therapeutics a démontré qu'Optejet peut délivrer du latanoprost avec une exposition significativement réduite à des conservateurs nocifs par rapport aux gouttes oculaires traditionnelles, évitant ainsi la cytotoxicité associée à des volumes plus importants. De plus, une étude de Phase 4 sur Mydcombi, présentée à l'American Academy of Optometry, a montré qu'une demi-dose a permis une dilatation pupillaire cliniquement pertinente avec des résultats de sécurité favorables. L'étude a rapporté des changements moyens du diamètre pupillaire de 2,74 mm au départ à 6,42 mm après 30 minutes, avec 67 % des yeux dilatés à ≥6 mm.

Eyenovia (NASDAQ: EYEN) hat zwei bedeutende Entwicklungen für seinen Optejet®-Dispenser angekündigt. Eine Studie, die im Journal of Ocular Pharmacology and Therapeutics veröffentlicht wurde, zeigte, dass Optejet latanoprost mit signifikant geringerer Exposition gegenüber schädlichen Konservierungsstoffen im Vergleich zu herkömmlichen Augentropfen abgeben kann, wodurch die mit größeren Volumina verbundene Zytotoxizität vermieden wird. Darüber hinaus zeigte eine Phase-4-Studie zu Mydcombi, die auf der American Academy of Optometry vorgestellt wurde, dass eine halbe Dosis eine klinisch relevante Pupillenerweiterung mit günstigen Sicherheitsprofilen erreichte. Die Studie berichtete von durchschnittlichen Änderungen des Pupillendurchmessers von 2,74 mm zu Beginn auf 6,42 mm nach 30 Minuten, wobei 67 % der Augen auf ≥6 mm erweitert waren.

Positive
  • Optejet demonstrates ability to deliver medication with 80% less volume than traditional eye drops
  • Study shows reduced exposure to harmful preservatives while maintaining therapeutic efficacy
  • Phase 4 study confirms effectiveness of half-dose administration, potentially expanding product applications
  • Favorable safety profile with only mild adverse events reported in clinical study
Negative
  • None.

Insights

The publication of this study represents a significant scientific advancement for Eyenovia's Optejet technology. The research demonstrates two key findings: 80% reduction in preservative exposure while maintaining therapeutic efficacy and successful pupil dilation with half-dose administration.

The preservative reduction finding is particularly important as BAK-related ocular surface toxicity is a major concern in ophthalmology. The ability to achieve therapeutic effects with reduced preservative exposure could lead to better treatment adherence and fewer side effects. This opens opportunities for reformulating existing medications using Optejet technology.

The Phase 4 study results showing effective pupil dilation with half-doses (67% of eyes reaching ≥6mm dilation) and faster recovery time provides clinical validation for dose optimization. This flexibility in dosing could be particularly valuable for specific patient populations requiring shorter duration procedures.

Publication in the Journal of Ocular Pharmacology and Therapeutics highlights the ability of the Optejet to achieve a therapeutic dose of medication with far less exposure to harmful preservatives

Additional presentation at the American Academy of Optometry summarizes a Phase 4 study of Mydcombi demonstrating that clinically relevant mydriasis can be achieved with a half-dose per eye

NEW YORK, Oct. 23, 2024 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), an ophthalmic technology company, today announced a publication in the Journal of Ocular Pharmacology and Therapeutics as well as an upcoming presentation at the American Academy of Optometry’s “Academy 2024 Indianapolis” Annual Meeting.

Publication in the Journal of Ocular Pharmacology and Therapeutics

The peer-reviewed paper highlights the ability of Eyenovia’s proprietary Optejet dispenser to deliver a therapeutic dose of latanoprost with far less exposure to the preservative benzalkonium chloride (BAK) than traditional eye drops. BAK, in larger volumes, can cause unwanted side effects, including cytotoxicity, cytoplasmic shrinkage, and loss of cell-cell contact, and expression of chemokine (C-C motif) ligand 2 and interleukin-6 (markers of inflammation).

In contrast, this in-vitro study of latanoprost plus BAK delivered in the same amount by the Optejet dispenser (8 microliters) avoided the cytotoxicity associated with larger volumes found in eye drops and was similar to no treatment controls and BAK-free latanoprost drops.  

“We have shown in prior studies the ability of the Optejet dispenser to achieve a therapeutic dose of medication with approximately 80% less volume and exposure to harmful preservatives than traditional eye drops,” stated Michael Rowe, Chief Executive Officer of Eyenovia. “The implication here is that preserved medications may not need to be reformulated to get many of the benefits of non-preserved products if delivered with the Optejet. We believe this creates potential opportunities for the Optejet to improve the administration of topical ocular therapeutics well beyond our own development pipeline.”

Presentation at the American Academy of Optometry’s “Academy 2024”

Eyenovia also announced today an upcoming presentation at the American Academy of Optometry’s “Academy 2024 Indianapolis,” which is being held November 6-9, in Indianapolis, IN.

The presentation details the results of an open-label Phase 4 study of 1% tropicamide and 2.5% phenylephrine ophthalmic metered spray, similar to Mydcombi, Eyenovia’s commercially available product for inducing mydriasis.

Twenty-nine subjects completed the study and administered one spray. Baseline pupil diameter (PD) for all eyes was 2.74±0.48 mm. Mean change in PD from baseline to 30 minutes was 3.69±1.25 mm. At 30 minutes post-dosing, mean PD was 6.42±1.25 mm, with 67% and 43% of eyes dilated to ≥ 6mm and 7mm, respectively. The majority of patients returned to functional vision (PD ≤ 5 mm) as early as 3.5 hours post-instillation, with 93% reaching that point by six hours. Safety outcomes were favorable, as only mild adverse events were reported (dry eye and mild instillation site pain) all of which resolved without intervention.

“We conducted this study to address questions from doctors about modulating dosing for patients who may benefit from a lower dose of tropicamide or phenylephrine,” stated Dr. Julie Whitcomb, Senior Director of Medical Affairs at Eyenovia. “What we found in this study was that a half dose may also provide clinically relevant pupil dilation, was well-tolerated, and had a desirable shorter duration of effect.”

Presentation details:

Title:An Open Label, Phase 4 Study of the Safety and Efficacy of Fixed Combination Tropicamide 1% and Phenylephrine 2.5% Ophthalmic Spray (MydCombi®)
Poster:#109, Exhibit Hall H
Presenter:Dr. Josianne Manasse, OD, SUNY College of Optometry
Date/time:Friday, November 8th, 1:00-3:00pm
  

For additional information on the Expo: https://aaopt.org/meetings/academy-2024-indianapolis/

About Eyenovia, Inc.

Eyenovia, Inc. (NASDAQ: EYEN) is an ophthalmic technology company developing a pipeline of advanced products based on its Optejet platform. Eyenovia is currently focused on the commercialization of Mydcombi® for mydriasis, clobetasol propionate ophthalmic suspension, 0.05% for post-surgical pain and inflammation, as well as the ongoing late-stage development of medications in the Optejet device for pediatric progressive myopia as well as out-licensing for additional indications. For more information, visit Eyenovia.com.

The Eyenovia Corporate Information slide deck may be found at ir.eyenovia.com/events-and-presentations.

PLEASE GO TO MYDCOMBI.COM FOR IMPORTANT SAFETY INFORMATION for MYDCOMBI™ (tropicamide and phenylephrine hydrochloride ophthalmic spray) 1%/2.5%

PLEASE GO TO CLOBETASOLBID.COM FOR IMPORTANT SAFETY INFORMATION for Clobetasol Propionate Ophthalmic Suspension 0.05%

Forward-Looking Statements
Except for historical information, all the statements, expectations and assumptions contained in this press release are forward-looking statements. Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions or any other statements relating to our future activities or other future events or conditions, including the timing and scale of acceptance and use of our approved products. These statements are based on current expectations, estimates and projections about our business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Therefore, actual outcomes and results may, and in some cases are likely to, differ materially from what is expressed or forecasted in the forward-looking statements due to numerous factors discussed from time to time in documents which we file with the U.S. Securities and Exchange Commission.

In addition, such statements could be affected by risks and uncertainties related to, among other things: risks of our clinical trials, including, but not limited to, the costs, design, initiation and enrollment, timing, progress and results of such trials; the timing of, and our ability to submit applications for, obtaining and maintaining regulatory approvals for our products and product candidates; the potential advantages of our products, product candidates and platform technology; the rate and degree of market acceptance and clinical utility of our products and product candidates; our estimates regarding the potential market opportunity for our products and product candidates; reliance on third parties to develop and commercialize our products and product candidates; the ability of us and our partners to timely develop, implement and maintain manufacturing, commercialization and marketing capabilities and strategies for our products and product candidates; intellectual property risks; changes in legal, regulatory, legislative and geopolitical environments in the markets in which we operate and the impact of these changes on our ability to obtain regulatory approval for our products and product candidates; and our competitive position.

Any forward-looking statements speak only as of the date on which they are made, and except as may be required under applicable securities laws, Eyenovia does not undertake any obligation to update any forward-looking statements.

Eyenovia Contact:
Eyenovia, Inc.
Andy Jones
Chief Financial Officer
ajones@eyenovia.com
Eyenovia Investor Contact:
Eric Ribner
LifeSci Advisors, LLC
eric@lifesciadvisors.com
(646) 751-4363
Eyenovia Media Contact:
Eyenovia, Inc.
Norbert Lowe
Vice President, Commercial Operations
nlowe@eyenovia.com

FAQ

What were the key findings of Eyenovia's (EYEN) Optejet study published in 2024?

The study showed Optejet can deliver latanoprost with significantly less exposure to BAK preservative than traditional eye drops, avoiding cytotoxicity while maintaining therapeutic effectiveness.

What were the pupil dilation results in Eyenovia's (EYEN) Phase 4 Mydcombi study?

The study showed mean pupil diameter increased from 2.74mm to 6.42mm after 30 minutes, with 67% of eyes dilated to ≥6mm and 43% to ≥7mm using a half-dose.

How long did pupil dilation effects last in Eyenovia's (EYEN) Mydcombi Phase 4 study?

The majority of patients returned to functional vision (pupil diameter ≤5mm) as early as 3.5 hours post-instillation, with 93% reaching that point by six hours.

Eyenovia, Inc.

NASDAQ:EYEN

EYEN Rankings

EYEN Latest News

EYEN Stock Data

9.00M
77.81M
9.99%
13.73%
2.49%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
NEW YORK